Company profile
Dogwood Therapeutics, Inc.
Pipeline4 assets
- Halneuron® NaV1.7 InjectionHAL / Halneuron® / NaV1.7 / subcutaneous small-molecule/peptide analgesic injection / Pain / neuropathyChemotherapy-induced neuropathic pain (CINP)Phase 2bOngoing; FDA Fast Track designationU.S.General cancer painPhase 2aCompleteAcute surgical painPreclinical
- SP16 Intravenous AdministrationSP16 IV / LRP1 agonist / IV peptide therapeutic / Neuropathy / cancer-related painChemotherapy-induced peripheral neuropathy (CIPN)Phase 1bNCI funded / forthcoming
- IMC-1IMC-1 / Herpesvirus suppression / COX-2 inhibition / Fixed-dose combination of anti-herpesvirus medication and COX-2 inhibitor / Pain / fatigue illnessFibromyalgiaPhase 2aPreviously demonstrated efficacy; disclosed as a novel therapeutic under antiviral combinations
- IMC-2IMC-2 / Herpesvirus suppression / COX-2 inhibition / Fixed-dose combination of anti-herpesvirus medication and COX-2 inhibitor / Pain / fatigue illnessLong COVIDOpen-label investigator-initiated study completed/reported; disclosed as a novel therapeutic under antiviral combinations
Latest news11 items
All newsDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
Enrollment • Phase 2Enrollment milestone Mon, Sep 14, 2026, 8:45 AM EDT
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
Results Call • Phase 2Results call Tue, Sep 1, 2026, 10:00 AM ET
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
Enrollment • Phase 2Enrollment milestone Thu, Aug 13, 2026, 8:30 AM EDT
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Enrollment • Phase 2Enrollment milestone Mon, Jul 20, 2026, 8:30 AM EDT
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Trial Start • Phase 2Trial initiation Mon, May 18, 2026, 8:45 AM EDT
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
Enrollment • Phase 2